Hong Jian
Overview
Explore the profile of Hong Jian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, et al.
Lung Cancer
. 2024 Aug;
195:107901.
PMID: 39089004
Background: In the initial analysis of a pivotal phase 2 single-arm study (NCT03861156), befotertinib (D-0316) showed clinical benefit with a manageable safety profile in pretreated patients with EGFR T790M mutated...
2.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al.
Cancer Commun (Lond)
. 2024 Jul;
44(9):1005-1017.
PMID: 39016053
Background: The initial randomized, double-blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor (EGFR)-mutated...
3.
Li Z, Song Z, Hong W, Yang N, Wang Y, Jian H, et al.
Signal Transduct Target Ther
. 2024 Jul;
9(1):182.
PMID: 39004647
A dose-escalation and expansion, phase 1/2 study (ClinicalTrials.gov, NCT04818333) was conducted to assess the novel antibody-drug conjugate SHR-A1811 in pretreated HER2-altered advanced non-small cell lung cancer (NSCLC). Here, we report...
4.
Lu S, Zhou J, Jian H, Wu L, Cheng Y, Fan Y, et al.
Lancet Respir Med
. 2023 May;
11(10):905-915.
PMID: 37244266
Background: Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as...
5.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, et al.
Lancet Respir Med
. 2023 May;
11(7):624-636.
PMID: 37156249
Background: In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and cisplatin) significantly improved progression-free survival in patients...
6.
Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, et al.
J Thorac Oncol
. 2023 Mar;
18(7):940-951.
PMID: 36948246
Introduction: D-1553 (garsorasib) is a potent and selective oral KRAS inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D-1553 in patients with KRAS G12C-mutated NSCLC...
7.
Xiao Y, Liao Y, Hou J, Li L, Xu T, Ma F, et al.
Open Life Sci
. 2022 Dec;
17(1):1568-1578.
PMID: 36561499
In this study, the data of fertility indicators of soil samples (0-20 cm) in 1980s, 2000 and 2015 in Chenzhou city were used, and the soil integrated fertility index (IFI)...
8.
Gu L, Ji W, Xu Y, Han Y, Jian H
Medicine (Baltimore)
. 2022 Dec;
101(47):e31480.
PMID: 36451418
Introduction: RET-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors...
9.
Xu Y, Gu L, Li Y, Zhao R, Jian H, Xie W, et al.
Front Oncol
. 2022 Nov;
12:1024818.
PMID: 36338758
Background: Non-small cell lung cancer (NSCLC) driven by exon 14 skipping (ex14) occurs in 3-4% of NSCLC cases and defines a subset of patients with distinct characteristics. While MET targeted...
10.
Gu L, Wang X, Sun Y, Xu Y, Niu X, Zhao R, et al.
Front Immunol
. 2022 Sep;
13:938269.
PMID: 36059450
Background: An open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable locally advanced...